
Valencia, Iliana

From: Valencia, Iliana
Sent: Thursday, June 23, 2016 6:17 PM
To: 'jcastillo@portola.com'
Subject: BLA 125586/0 Coagulation Factor Xa (Recombinant), Inactivated - Information Request
Portola Pharmaceuticals Inc.
Attention: Ms. Janice Castillo
June 23, 2016 Sent
by email

Dear Ms. Castillo:

We are reviewing your December 17, 2015 biologics license application (BLA) for 125586/0 Coagulation Factor Xa (Recombinant), Inactivated.

We have reviewed the certificates of analysis provided with your samples for testing on 29 February, 2016, as part of your submission under STN 125586/0.8 and have the following request:

Direct and Indirect Potency Assays

Please provide your results for the Direct (b) (4), using TME-0580, and Indirect (b) (4), using TME-0583, for the following lots of drug product submitted to CBER for testing:

- M7173A
- M7177A

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your responses as an amendment to this file by **July 6, 2016**. If you are unable to do so, please let me know so that we can discuss a possible alternate time for submission.

The action due date for these files is August 17, 2016.

Sincerely,

Iliana Valencia, MS, MCPM
Chief, Regulatory Project Management Staff
FDA/CBER/OBRR/IO 240-402-
8444 iliana.valencia@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."